Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing

Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing

Publication date: May 29, 2020

Mike Janicek, MD, and Bradley J. Monk, MD, FACS, FACOG, prepared useful Practice Aids pertaining to DDR-mutant cancers and PARP inhibitors for this CME activity titled, “Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing.” For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2T8MPzj. CME credit will be available until May 26, 2021.

PDF

Concepts Keywords
Abdominal Pain Cancers
Acute Myeloid Leukemia MDS myelodysplastic syndromes
Adjuvant Vomiting
Alanine Transaminase Eects hypertension
ALK TMB tumor
ALT Fallopian tube cancer
Aminotransferase Approvedcommercial tumor
Androgen Receptor AppetiteConstitutional fatigue
Anemia Breast Cancer
Ashkenazi Jewish PML promyelocytic leukemia
Aspartate Chemotherapy
AST Chemotherapies
Asthenia Endocrine therapy
Biopsy Branches of biology
Blood Medicine
BRCA Mutation RTT
BRCA1 Hereditary cancers
Breakpoint Lactams
Breast PARP inhibitors
CAMP Triple-negative breast cancer
Cancer BRCA mutation
Castration BRCA1
Catalytic Olaparib
Chemotherapies ROS1
Chemotherapy Alpha
Constipation Single nucleotide polymorphism
Creatinine Recombination
Diarrhea Pdf
Dysgeusia Chemotherapy
EGFR
Endocrine Therapy
Enzalutamide
Epithelial
ETV6
Exocrine
FACS
Fallopian Tube
Fatigue
FDA
Fda
Fetal
FGFR
Formalin
Gene
Genetic Testing
Genomic Instability
Germline
GIS
Gleason Score
HER2
HER2 Negative
Heterozygosity
Homolog
Homologous Recombination
Hormone
Hypertension
Immunohistochemistry
Kinase
Leukemia
Lymphoma
Metastatic
Mismatch Repair
Monk
MSI
Murine
Mutant
Myelodysplastic Syndromes
Nausea
NCCN
Neoadjuvant
Neurotrophic
Neutropenia
NTRK1
Oncogene
Oncology
Ovarian Cancer
Paraffin
PARP
Pathogenic
PDGFRA
PDGFRB
Peritoneal
Platelet
Platinum
PML
Polymerase
Prostate
Protein
Receptor
Receptor Tyrosine Kinase
Ribose
Sarcoma
Sequencing
Single Nucleotide Polymorphism
Somatic
Taxane
Telomere
Thrombocytopenia
TNBC
Transcription Factor
Tumor
Viral
Vomiting

Semantics

Type Source Name
disease MESH Aids
disease MESH cancers
drug DRUGBANK Coenzyme M
pathway KEGG Acute myeloid leukemia
drug DRUGBANK L-Alanine
pathway KEGG Homologous recombination
disease MESH myelodysplastic syndromes
drug DRUGBANK Niraparib
drug DRUGBANK Olaparib
drug DRUGBANK Rucaparib
drug DRUGBANK Talazoparib
drug DRUGBANK Cefadroxil
drug DRUGBANK Platinum
disease MESH ovarian cancer
disease MESH anemia
disease MESH thrombocytopenia
disease MESH neutropenia
disease MESH dysgeusia
disease MESH abnormalities
drug DRUGBANK Creatinine
disease MESH hypertension
drug DRUGBANK Enzalutamide
disease MESH epithelial ovarian cancer
disease MESH fallopian tube cancer
disease MESH triple negative breast cancer
disease MESH Breast Cancer
pathway KEGG Breast cancer
disease MESH Gleason score
disease MESH diagnosis
disease MESH Biopsy
drug DRUGBANK Lauric Acid
disease MESH leukemia
disease MESH lymphoma
disease MESH Ewing sarcoma
drug DRUGBANK Formaldehyde
disease MESH genomic instability
pathway KEGG Mismatch repair
disease MESH microsatellite instability
drug DRUGBANK L-Tyrosine
disease MESH growth
drug DRUGBANK Cyclic Adenosine Monophosphate
drug DRUGBANK Tretinoin
disease MESH allelic imbalance
drug DRUGBANK Serine
drug DRUGBANK Myricetin

Download Document

Leave a Comment

Your email address will not be published. Required fields are marked *